- Home
- EOSE vs IMCR Comparison
EOSE vs IMCR Comparison
Compare EOSE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOSE
- IMCR
- Stock Information
- Founded
- EOSE 2008
- IMCR 2008
- Country
- EOSE United States
- IMCR United Kingdom
- Employees
- EOSE N/A
- IMCR N/A
- Industry
- EOSE Industrial Machinery/Components
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EOSE Miscellaneous
- IMCR Health Care
- Exchange
- EOSE Nasdaq
- IMCR Nasdaq
- Market Cap
- EOSE 1.6B
- IMCR 1.8B
- IPO Year
- EOSE N/A
- IMCR 2021
- Fundamental
- Price
- EOSE $6.32
- IMCR $32.93
- Analyst Decision
- EOSE Strong Buy
- IMCR Buy
- Analyst Count
- EOSE 3
- IMCR 9
- Target Price
- EOSE $6.50
- IMCR $57.00
- AVG Volume (30 Days)
- EOSE 12.6M
- IMCR 331.8K
- Earning Date
- EOSE 07-30-2025
- IMCR 08-07-2025
- Dividend Yield
- EOSE N/A
- IMCR N/A
- EPS Growth
- EOSE N/A
- IMCR N/A
- EPS
- EOSE N/A
- IMCR N/A
- Revenue
- EOSE $33,800,000.00
- IMCR $356,145,000.00
- Revenue This Year
- EOSE $945.82
- IMCR $27.43
- Revenue Next Year
- EOSE $195.86
- IMCR $8.64
- P/E Ratio
- EOSE N/A
- IMCR N/A
- Revenue Growth
- EOSE 128.49
- IMCR 26.78
- 52 Week Low
- EOSE $2.06
- IMCR $23.15
- 52 Week High
- EOSE $7.36
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- EOSE 56.22
- IMCR 48.44
- Support Level
- EOSE $5.77
- IMCR $32.07
- Resistance Level
- EOSE $6.40
- IMCR $33.20
- Average True Range (ATR)
- EOSE 0.39
- IMCR 1.35
- MACD
- EOSE -0.06
- IMCR 0.05
- Stochastic Oscillator
- EOSE 48.25
- IMCR 69.04
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.